Guideline: Screening for prostate cancer (Republic of Cyprus): Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
'''Access to information:''' [https://www.moh.gov.cy/moh/moh.nsf/bf38a2d2e174417cc225782600313992/3b7c3521a6e9a1bbc2257cf30028391c?OpenDocument Click here to access]. | '''Access to information:''' [https://www.moh.gov.cy/moh/moh.nsf/bf38a2d2e174417cc225782600313992/3b7c3521a6e9a1bbc2257cf30028391c?OpenDocument Click here to access]. | ||
{{Prostate}} | |||
{{Testicles}} | |||
{{Penis}} | |||
Revision as of 17:53, 12 September 2024
Go back to Republic of Cyprus page
Primary purpose: To outline the risk assessment and recommended procedures for PSA testing to detect prostate cancer.
Sponsor, manager or home institution: Ministry of Health and Health Insurance Organization.
Type of information: This guideline provides risk percentages for prostate cancer based on PSA levels, along with screening recommendations considering age, race, family history, and other factors affecting PSA results. It also includes guidance on when to pursue further diagnostic procedures and highlights the importance of individualized patient-physician discussions. diagnosis, medical procedures, age, screening, check-up examinations.
Cancer Areas of Interest: C60-C63: Male genitalia cancer. Click here to learn more.
Access to information: Click here to access.
